1. Market Research
  2. > Pharmaceutical Market Trends
  3. > High Point Pharmaceuticals, LLC - Product Pipeline Review - 2014

High Point Pharmaceuticals, LLC - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 28 pages

High Point Pharmaceuticals, LLC - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘High Point Pharmaceuticals, LLC - Product Pipeline Review - 2014’, provides an overview of the High Point Pharmaceuticals, LLC’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of High Point Pharmaceuticals, LLC’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of High Point Pharmaceuticals, LLC including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of High Point Pharmaceuticals, LLC’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the High Point Pharmaceuticals, LLC’s pipeline products

Reasons to buy

- Evaluate High Point Pharmaceuticals, LLC’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of High Point Pharmaceuticals, LLC in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the High Point Pharmaceuticals, LLC’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of High Point Pharmaceuticals, LLC and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of High Point Pharmaceuticals, LLC
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of High Point Pharmaceuticals, LLC and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

High Point Pharmaceuticals, LLC - Product Pipeline Review - 2014
Table of Contents
High Point Pharmaceuticals, LLC Snapshot 5
High Point Pharmaceuticals, LLC Overview 5
Key Information 5
Key Facts 5
High Point Pharmaceuticals, LLC - Research and Development Overview 6
Key Therapeutic Areas 6
High Point Pharmaceuticals, LLC - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
High Point Pharmaceuticals, LLC - Pipeline Products Glance 10
High Point Pharmaceuticals, LLC - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
High Point Pharmaceuticals, LLC - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
High Point Pharmaceuticals, LLC - Drug Profiles 13
HPP-404 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
HPP-851 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
HPP-593 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
HPP-854 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
HPP-737 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
HPP-971 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
High Point Pharmaceuticals, LLC - Pipeline Analysis 19
High Point Pharmaceuticals, LLC - Pipeline Products by Target 19
High Point Pharmaceuticals, LLC - Pipeline Products by Route of Administration 20
High Point Pharmaceuticals, LLC - Pipeline Products by Molecule Type 21
High Point Pharmaceuticals, LLC - Pipeline Products by Mechanism of Action 22
High Point Pharmaceuticals, LLC - Recent Pipeline Updates 23
High Point Pharmaceuticals, LLC - Dormant Projects 24
High Point Pharmaceuticals, LLC - Company Statement 25
High Point Pharmaceuticals, LLC - Locations And Subsidiaries 26
Head Office 26
Appendix 27
Methodology 27
Coverage 27
Secondary Research 27
Primary Research 27
Expert Panel Validation 27
Contact Us 28
Disclaimer 28

List of Tables

High Point Pharmaceuticals, LLC, Key Information 5
High Point Pharmaceuticals, LLC, Key Facts 5
High Point Pharmaceuticals, LLC - Pipeline by Indication, 2014 7
High Point Pharmaceuticals, LLC - Pipeline by Stage of Development, 2014 8
High Point Pharmaceuticals, LLC - Monotherapy Products in Pipeline, 2014 9
High Point Pharmaceuticals, LLC - Phase II, 2014 10
High Point Pharmaceuticals, LLC - Phase I, 2014 11
High Point Pharmaceuticals, LLC - Preclinical, 2014 12
High Point Pharmaceuticals, LLC - Pipeline by Target, 2014 19
High Point Pharmaceuticals, LLC - Pipeline by Route of Administration, 2014 20
High Point Pharmaceuticals, LLC - Pipeline by Molecule Type, 2014 21
High Point Pharmaceuticals, LLC - Pipeline Products by Mechanism of Action, 2014 22
High Point Pharmaceuticals, LLC - Recent Pipeline Updates, 2014 23
High Point Pharmaceuticals, LLC - Dormant Developmental Projects,2014 24

List of Figures

High Point Pharmaceuticals, LLC - Pipeline by Top 10 Indication, 2014 7
High Point Pharmaceuticals, LLC - Pipeline by Stage of Development, 2014 8
High Point Pharmaceuticals, LLC - Monotherapy Products in Pipeline, 2014 9
High Point Pharmaceuticals, LLC - Pipeline by Top 10 Target, 2014 19
High Point Pharmaceuticals, LLC - Pipeline by Top 10 Route of Administration, 2014 20
High Point Pharmaceuticals, LLC - Pipeline by Top 10 Molecule Type, 2014 21
High Point Pharmaceuticals, LLC - Pipeline Products by Top 10 Mechanism of Action, 2014 22

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.